TABLE 3.
Features of Liver-Directed Non-Viral Gene Therapy Methods
| Method | Integration and persistence | In vivo gene transfer efficiency to liver | Liver-specificity | Immunological*, integration site and transgene size |
|---|---|---|---|---|
|
| ||||
| NON-VIRAL VECTORS: | ||||
| Sleeping Beauty Transposons | Permanent | High efficiency | Liver targeted | Probably non-immunogenic; preferentially inserts transgenes into TA dinucleotide sites in nontranscribed and intronic regions; ~10kB - efficiency decreases with transgene size |
| PiggyBac Transposons | Permanent | High efficiency | Liver targeted | Probably non-immunogenic; ability to integrate relatively large transgenes (up to 100-kb); TTAA target sequences |
| PhiC31 Integrase | Permanent | High efficiency | Liver targeted | Probably non-immunogenic; unlimited transgene size; integrates in mammalian genome at pseudo attP sites |